LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?

Eli Lilly (LLY) is presented as the preferred investment over Novo Nordisk (NVO) in the competitive GLP-1 diabetes and obesity market, despite LLY's higher valuation. Lilly anticipates over 30% revenue growth in 2025, driven by strong Mounjaro and Zepbound sales which now comprise half its revenue, and a diversified pipeline, leading to rising analyst estimates. Conversely, Novo Nordisk has significantly lowered its 2025 sales and profit outlook due to persistent supply constraints, escalating competition from LLY's lower-priced products, and pipeline setbacks, resulting in declining analyst forecasts and a substantial stock decline. The broader $100 billion obesity market is experiencing intense competition, with both firms and new entrants actively developing next-generation and oral GLP-1 therapies.

Analysis

Eli Lilly (LLY) and Novo Nordisk (NVO) are exhibiting sharply diverging trajectories within the competitive GLP-1 market. Lilly is demonstrating significant momentum, forecasting 2025 revenues of $60-$62 billion, representing over 30% year-over-year growth, with its Mounjaro and Zepbound products now accounting for approximately 50% of total revenue. This growth is supported by rising EPS estimates, a higher return on equity (92.7%), and a strategic diversification into oncology and neuroscience through recent M&A activities. Despite a high forward P/E of 25.92 and some pricing pressure, Lilly's more diversified business model—with its Cardiometabolic Health segment at 77% of revenue—positions it favorably. Conversely, Novo Nordisk is facing considerable headwinds, having sharply cut its 2025 sales and profit outlook due to supply constraints, eroding pricing power evidenced by Wegovy price cuts, and slower market adoption. This has contributed to a 30.9% year-to-date stock decline, falling EPS estimates, and a Zacks #5 (Strong Sell) rating. NVO's heavy reliance on its Diabetes and Obesity care segment, which constitutes 93.8% of total sales, magnifies its vulnerability to these pressures and pipeline setbacks like the underwhelming CagriSema data. The broader obesity market, projected to reach $100 billion by 2030, is also heating up with new entrants like Amgen, Viking Therapeutics, and Pfizer's acquisition of Metsera, signaling intensifying long-term competition for both incumbents.

Key Decisions for Investors

• Investors may consider Eli Lilly's premium valuation justified given its strong revenue growth forecast of over 30%, rising EPS estimates, and strategic diversification, which provides a buffer against concentration risk in the GLP-1 space.
• Extreme caution is warranted for Novo Nordisk due to its significant 2025 guidance cut, falling analyst estimates, and intense competitive and pricing pressures, making it prudent to await signs of operational stabilization before considering an investment.
• Monitor the competitive landscape closely, as the entry of players like Amgen, Viking Therapeutics, and Pfizer into the obesity market could erode the market share and pricing power of both Lilly and Novo Nordisk over the long term.
• For income-focused investors, Novo Nordisk's higher dividend yield of 2.4% compared to Lilly's 0.8% must be weighed against its significant stock price volatility and negative business momentum.